Loading...
Please wait, while we are loading the content...
Similar Documents
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients
| Content Provider | Scilit |
|---|---|
| Author | Rallón, Norma Naggie, Susanna Benito, José M. Medrano, José Restrepo, Clara Goldstein, David Shianna, Kevin V. Vispo, Eugenia Thompson, Alex McHutchison, John Soriano, Vincent |
| Copyright Year | 2010 |
| Description | Journal: Aids Background: Given that peginterferon–ribavirin treatment is poorly tolerated, there is interest in the identification of predictors of response, particularly in HIV/hepatitis C virus (HCV)-coinfected patients that respond less than HCV-monoinfected individuals. A single nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) has been shown to predict treatment response in HCV-monoinfected patients carrying genotype 1. Information is lacking for HIV/HCV-coinfected individuals and/or other HCV genotypes. Methods: From 650 HIV/HCV-coinfected patients, we identified those who had completed a course of peginterferon–ribavirin therapy with a validated outcome and available repository DNA. The rs12979860 SNP was examined in a blinded fashion. Results: A total of 164 patients were included in the final IL28B genotyping analysis, 90 (55%) of whom achieved sustained virological response (SVR). HCV genotype distribution was as follows: HCV-1 58%, HCV-3 31% and HCV-4 11%. Overall, the SVR rate was higher in patients with CC than in those CT/TT genotypes: 56 of 75 (75%) versus 34 of 89 (38%) (P < 0.0001). The effect of the SNP was seen in HCV genotypes 1 and 4 but not in HCV genotype 3 carriers. In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6–8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1–21.0; <0.001), serum HCV-RNA less than 600 000 IU/ml (11.9; 3.8–37.4; <0.001) and lack of advanced liver fibrosis (3.5; 1.4–8.9; 0.009). Conclusion: The rs12979860 SNP located near the IL28B gene is associated with HCV treatment response in HIV-infected patients with chronic hepatitis C due to genotypes 1 or 4. Thus, IL28B genotyping should be considered as part of the treatment decision algorithm in this difficult-to-treat population. |
| Related Links | http://europepmc.org/articles/pmc4892373?pdf=render https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892373/pdf |
| Ending Page | F29 |
| Page Count | 7 |
| Starting Page | F23 |
| ISSN | 02699370 |
| e-ISSN | 14735571 |
| DOI | 10.1097/qad.0b013e3283391d6d |
| Journal | Aids |
| Issue Number | 8 |
| Volume Number | 24 |
| Language | English |
| Publisher | Ovid Technologies (Wolters Kluwer Health) |
| Publisher Date | 2010-05-15 |
| Access Restriction | Open |
| Subject Keyword | Journal: Aids Genetic Polymorphism, Hepatitis C Virus Treatment, Hiv/hepatitis C Virus Coinfection, Interferon-λ, Il-28b, Pegylated Interferon, Rs12979860, Single Nucleotide Polymorphism |
| Content Type | Text |
| Resource Type | Article |
| Subject | Infectious Diseases Immunology and Allergy Immunology |
